Are we Closer to Symptom Management or a Cure for Alzheimer’s?

September 30, 2022

Biogen and Eisai released topline data Wednesday from the global Phase III study of lecanemab, an anti-amyloid beta antibody that reportedly resulted in a “highly statistically significant” reduction in Alzheimer’s disease progression. This provides an opportunity to stop and consider whether science is closer to a cure or symptom management in this space.

In a Sept. 27 statement, the Alzheimer’s Association called the news “the most encouraging results in clinical trials treating the underlying causes of Alzheimer’s to date.”

The news came on the heels of more than a year of controversy in the space. In June, Biogen canceled a separate observational study of the beta-amyloid-clearing drug Aduhelm (aducanumab-avwa) after just 29 patients signed up. Aduhelm is the first FDA-approved treatment to address the biology underlying AD.

Read the full artcle here: https://www.biospace.com/article/are-we-closer-to-symptom-management-or-a-cure-for-alzheimer-s-/